Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
Related Experiment Video
Updated: Jan 24, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
1From the Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially over the past few years. Although the data are preliminary at this time, the results have garnered much enthusiasm in the field. Immune therapies targeting B-cell maturation antigen have been the most widely developed, and much of these early data were presented at the recent American Society of Hematology 2018 meeting. Here we review the available data for anti-B-cell maturation antigen CAR T-cell therapies and discuss next steps as the field progresses forward.
Insights
Chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen show promise for multiple myeloma, an incurable cancer. Further research is needed to advance these novel immune therapies.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Multiple myeloma remains an incurable malignancy with significant unmet medical needs.
- Recent advancements in therapies have been made, yet a cure has not been achieved.
Purpose of the Study:
- To review available data on anti-B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma.
- To discuss the progression and next steps for these novel immune therapies.
Main Methods:
- Review of clinical investigations and data presented at the American Society of Hematology 2018 meeting.
- Focus on adoptive cellular therapies using CAR T-cells targeting B-cell maturation antigen.
Main Results:
- The number of CAR T-cell trials for multiple myeloma has increased exponentially.
- Preliminary data for anti-B-cell maturation antigen CAR T-cell therapies have generated significant enthusiasm.
Conclusions:
- CAR T-cell therapies, particularly those targeting B-cell maturation antigen, represent a promising avenue for treating multiple myeloma.
- Continued research and clinical investigation are crucial for advancing these therapies.
More Related Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Types of Receptors: Cell Surface Receptors
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...